137 related articles for article (PubMed ID: 17589338)
1. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy.
Ellis D; Shapiro R; Moritz M; Vats A; Basu A; Tan H; Kayler L; Janosky J; Starzl TE
Transplantation; 2007 Jun; 83(12):1563-70. PubMed ID: 17589338
[TBL] [Abstract][Full Text] [Related]
2. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.
Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Khan AS; Gray EA; Zeevi A; McFeaters C; James G; Jo Grosso M; Marcos A; Starzl TE
J Pediatr; 2006 Jun; 148(6):813-8. PubMed ID: 16769394
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
[TBL] [Abstract][Full Text] [Related]
4. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.
Tan HP; Donaldson J; Ellis D; Moritz ML; Basu A; Morgan C; Vats AN; Erkan E; Shapiro R
Transplantation; 2008 Dec; 86(12):1725-31. PubMed ID: 19104412
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.
Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Kayler LK; Erkan E; McFeaters CG; James G; Grosso MJ; Zeevi A; Gray EA; Marcos A; Starzl TE
Am J Transplant; 2007 Dec; 7(12):2736-8. PubMed ID: 17908272
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients.
Sung J; Barry JM; Jenkins R; Rozansky D; Iragorri S; Conlin M; Al-Uzri A
Pediatr Transplant; 2013 Dec; 17(8):718-25. PubMed ID: 24164824
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
9. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
Tan HP; Kaczorowski D; Basu A; McCauley J; Marcos A; Donaldson J; Unruh M; Randhawa P; Zeevi A; Shapiro R
Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
11. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
[TBL] [Abstract][Full Text] [Related]
14. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
Tan HP; Donaldson J; Basu A; Unruh M; Randhawa P; Sharma V; Morgan C; McCauley J; Wu C; Shah N; Zeevi A; Shapiro R
Am J Transplant; 2009 Feb; 9(2):355-66. PubMed ID: 19120078
[TBL] [Abstract][Full Text] [Related]
15. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
16. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
[TBL] [Abstract][Full Text] [Related]
17. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.
Tan HP; Kaczorowski DJ; Basu A; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplantation; 2004 Dec; 78(11):1683-8. PubMed ID: 15591960
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
19. Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation.
Puliyanda DP; Pizzo H; Rodig N; Somers MJG
Pediatr Transplant; 2020 May; 24(3):e13685. PubMed ID: 32112514
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
